What if we applied plant biotechnology for dermocosmetic care? Vytrus Biotech, an industrial company listed on the BME Growth market since 2022, has been betting on technological innovation based on plant stem cell technology for 15 years.
The company develops, produces and markets active ingredients with high added value for the dermocosmetic and healthcare industries. Developing its active ingredients from plant stem cells for skin and hair care, Vytrus markets its ingredients to cosmetic manufacturers and brands in nearly 40 countries on 5 continents. Ingredients with high technological potential developed and produced on an industrial scale in its facilities of more than 1,400m2, with its own laboratory and production plant.
At the level of innovation, its technology allows the creation of very effective and patentable 100% natural assets; constant and unlimited supply, under conditions of controlled production independent of natural resources; and a potential for application to other strategic sectors (pharmaceutical, veterinary, functional food, etc.).
Vytrus has developed a business model that offers a significant return to the investor and society. The combination of profitability & Innovation & Sustainability are inseparable in the Vytrus project.
In the area of social profitability, Vytrus has been recognized with more than 20 international and national innovation awards, in addition to 9 patent applications. At a sustainability level, its “lab-grown” production process has led the company to generate savings of more than 140 thousand tons of water in the last 5 years compared to traditional plant extracts, generating a positive impact in the fight against climate change.
In the area of economic profitability, in the last 4 years Vytrus has accumulated a CAGR (Compound Annual Growth Rate) of its sales greater than 30% and an average EBITDA of 37% in the same period. In the first 6 months of 2024, the company has achieved sales of 2.5 million euros (+28% compared to 2023) and an EBITDA of 1 million euros (+35% compared to 2023). The average profit after taxes of the company in the last 4 years has been 16%, with the Net financial debt/EBITDA ratio at X 0.3 as of June 2024.
In BME Growth, the company has accumulated a revaluation of +30% since its debut as a listed company in March 2022. In 2024, Vytrus’ operations in the secondary market have moved more than 760 thousand shares for an amount of more than 1.7 million euros.
The company recently published its 2027 Strategic Plan, one of its pillars being the transformation into a multitechnology company in the cosmetic active ingredients sector. To accelerate growth and reach more customers, the company will incorporate new innovative technologies complementary to plant stem cells for application in dermocosmetics and will launch active ingredients based on them on the market for the first time. Strategic agreements and inorganic operations to access these technologies will make Vytrus a multi-technology group with the capacity to offer its B2B clients a broader range of innovative solutions. Furthermore, thanks to these investments in other companies, the team will have the challenge of turning Vytrus into a technological hub with enormous potential in the field of biotechnology.
In this sense, Vytrus expects an investment in 2024 around one million euros, which will grow gradually in the coming years, although the ratio to sales will decrease until reaching 15%, at the level of the companies in the sector that invest the most. in R&D&i.
In short, Vytrus offers high financial and social profitability, with an innovative and sustainable business model and financial metrics that show a company with a high capacity for business growth and scalability of its profits, in addition to a very healthy position in terms of to financial debt.